Study S001425

Effects of GLP-l Receptor Agonists on Cardiometabolic Alterations in HIV-associated Lipohypertrophy

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT04019197
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 108
Start: 2019-05-16
Primary completion: 2024-04-30
Lead sponsor: Case Western Reserve University
Conditions: HIV/AIDS; Lipohypertrophy; Obesity
Interventions: DRUG:Semaglutide Injectable Product; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: NIH:R01DK121619

Registered primary outcomes

Effects of Semaglutide on Quantity of Abdominal Fat (Total, Subcutaneous, Visceral) at Week 32 Compared to Baseline [32 weeks]
Effects of Semaglutide on Quantity of Fat (Total Body Fat, Limb Fat, Trunk Fat) at Week 32 Compared to Baseline [32 weeks]
Effects of Semaglutide on Quantity of Ectopic Fat (Total Pericardial Fat) at Week 32 Compared to Baseline [32 weeks]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0003693	Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial. Atieh O, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America	2026	Randomized trial	PMID 41098140 DOI	cites ClinicalTrials.gov:NCT04019197; registry reference DERIVED:41098140
R0007406	Semaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy. Corley MJ, Nature communications	2026	Randomized trial	PMID 42156721 DOI	cites ClinicalTrials.gov:NCT04019197
R0009056	Effects of semaglutide on subclinical cardiovascular health in people with HIV. Daher J, AIDS (London, England)	2026	Randomized trial	PMID 42752515 DOI	cites ClinicalTrials.gov:NCT04019197; registry reference DERIVED:42752515
R0056125	Durability of semaglutide effects after treatment discontinuation in HIV-associated lipohypertrophy: a randomized, double-blind, placebo-controlled phase IIb clinical trial Ruth O. Adekunle, Open Forum Infectious Diseases	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT04019197
R0017256	The Effects of Semaglutide on Inflammation and Immune Activation in HIV-associated Lipohypertrophy. Funderburg NT, Open forum infectious diseases	2025	Randomized trial	PMID 40160348 DOI	cites ClinicalTrials.gov:NCT04019197; registry reference DERIVED:40160348
R0004841	Are glucagon-like peptide 1 receptor agonists effective in decreasing body weight and body mass index in people living with diabetes and HIV? Bottanelli M, HIV medicine	2024	Nonrandomized study	PMID 37990373 DOI	cites ClinicalTrials.gov:NCT04019197
R0015327	Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial. Eckard AR, The lancet. Diabetes & endocrinology	2024	Randomized trial	PMID 38964353 DOI	cites ClinicalTrials.gov:NCT04019197; registry reference DERIVED:38964353